XTX Topco’s TG Therapeutics TGTX Stock Holding History

XTX Topco’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,583	Closed	-$850K	–	4697
2026 Q1	$850K	Buy	+25,583	New	+$762K	0.01%	1561
2025 Q4	–	Sell	-47,918	Closed	-$1.73M	–	3789
2025 Q3	$1.73M	Buy	+47,918	New	+$1.58M	0.09%	261
2025 Q2	–	Sell	-39,618	Closed	-$1.56M	–	3161
2025 Q1	$1.56M	Buy	39,618 +26,314	+198%	+$885K	0.08%	340
2024 Q4	$400K	Buy	+13,304	New	+$382K	0.03%	961
2024 Q3	–	Sell	-22,176	Closed	-$395K	–	2608
2024 Q2	$395K	Buy	+22,176	New	+$354K	0.03%	793
2023 Q4	–	Sell	-19,999	Closed	-$167K	–	2140
2023 Q3	$167K	Buy	19,999 +4,623	+30%	+$64.5K	0.03%	1074
2023 Q2	$382K	Buy	+15,376	New	+$397K	0.07%	547
2023 Q1	–	Sell	-17,695	Closed	-$209K	–	1656
2022 Q4	$209K	Sell	17,695 -18,118	-51%	-$131K	0.04%	813
2022 Q3	$212K	Sell	35,813 -1,206	-3%	-$7.91K	0.05%	746
2022 Q2	$157K	Buy	+37,019	New	+$231K	0.06%	528

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

XTX Topco's TGTX Position: Q2 2026 in Review

XTX Topco sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 25,583 shares — an estimated $850K sold.

XTX Topco first reported a position in TGTX in Q2 2022 and held it in 10 quarters. The position peaked at $1.73M in Q3 2025. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

XTX Topco reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 25,583 TG Therapeutics shares in Q2 2026, an estimated $850K.
XTX Topco first reported a position in TG Therapeutics in Q2 2022 and held it in 10 quarters.
XTX Topco's TG Therapeutics position peaked at $1.73M in Q3 2025.
428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.